Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02147587 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

A Phase 2 study of Rheumatoid Arthritis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
112
Enrollment target
20
Study locations

NCT02147587 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 112 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02147587, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
112 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG Tofacitinib

Study Locations (20)

Florida

  • Jacksonville Center for Clinical Research - Jacksonville
  • Center for Arthritis and Rheumatic Diseases - Miami
  • Suncoast Clinical Research, Inc. - New Port Richey
  • DMI Research, Inc. - Pinellas Park
  • Florida Arthritis and Osteoporosis Center - Port Richey
  • Gulf Coast Medical Center - Port Richey
  • Sarasota Arthritis Research Center - Sarasota
  • Suncoast Medical Clinic - St. Petersburg
  • Sun Coast Medical Clinic - St. Petersburg
  • Health Point Medical Group, Inc. - Tampa

California

  • Drug Shipping Address (IRB# 14-000826) Ronald Regan - Los Angeles
  • UCLA David Geffen School of Medicine - Los Angeles
  • Pacific Arthritis Center Medical Group - Santa Maria
  • Inland Rheumatology Clinical Trials, Inc. - Upland

Arkansas

  • NEA Baptist Clinic - Jonesboro

Illinois

  • Deerbrook Medical Associates - Vernon Hills

Indiana

  • Diagnostic Rheumatology And Research, PC - Indianapolis

Maryland

  • Arthritis Treatment Center - Frederick

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

New York

  • The Center for Rheumatology, LLP - Albany

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2014-06
Est. Completion 2015-07
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02147587

The ClinicalTrials.gov registry entry for NCT02147587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02147587 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02147587 about?

NCT02147587 is a clinical study titled "A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate". This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.

What is the current status of trial NCT02147587?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2014-06. Estimated completion is 2015-07.

What conditions does trial NCT02147587 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02147587?

The interventions under investigation include: Placebo (DRUG), Tofacitinib (DRUG).

Who is sponsoring clinical trial NCT02147587?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02147587 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.